What are Therapeutic Peptides?
Therapeutic Peptides Are Quietly Rewriting Modern Medicine
From diabetes drugs to cancer-killing proteins — how a tiny class of molecules is becoming one of the most powerful tools in the pharmaceutical arsenal.
More than 80 peptide drugs have been approved globally as of 2023, and over 200 more are winding through clinical trials. These aren't just incremental improvements — they're targeting diseases that conventional medicine has long struggled with. Here's what you need to know.
When most people think about cutting-edge drugs, they picture antibodies, gene therapies, or small molecules. Therapeutic peptides — chains of amino acids usually between 2 and 50 residues long — tend to fly under the radar. But that's changing fast. Spanning molecular weights from 50 to 5,000 Da, these compounds occupy a unique sweet spot between small-molecule drugs and full biologics, offering the precision targeting of an antibody with the synthetic accessibility of a chemical compound.
Why Peptides? The Unique Advantages
To understand the excitement, you need to understand what makes therapeutic peptides different from everything else in the pharmacist's toolkit.
Small molecules are easy to manufacture and can cross cell membranes readily, but they struggle to engage large, flat protein surfaces — the kind involved in protein-protein interactions (PPIs) that drive many diseases. Large biologics like monoclonal antibodies excel at binding those surfaces but are expensive, immunogenic, and always injected. Peptides sit between these worlds: large enough to modulate complex interfaces, small enough to be chemically synthesised and chemically optimised.
"Their ability to engage large protein interaction surfaces enables modulation of protein–protein interactions, a feat often unattainable with small molecules."— Zheng, Wang, Guo & Tzeng (2025), International Journal of Molecular Sciences
Critically, peptides generally display lower immunogenicity than antibodies or proteins, which matters enormously in chronic disease management where patients take drugs for decades. Their structural versatility — amenable to cyclisation, PEGylation, fatty acid conjugation, and incorporation of non-natural amino acids — gives medicinal chemists an extraordinary canvas for optimisation.
But the picture is not uniformly rosy. Peptides are metabolically fragile. Proteolytic enzymes in the bloodstream and gut chew through them rapidly, and their poor oral bioavailability has historically confined them to injected formulations. Fewer than 10% of approved peptides act on intracellular targets — the rest are limited to extracellular receptors. Overcoming these challenges is where most of the contemporary research energy is directed.
Recently FDA-Approved Therapeutic Peptides
The clinical pipeline has been especially productive over the last few years. Below is a curated look at twelve recently approved agents, illustrating the remarkable breadth of conditions now accessible to peptide-based therapy.
| Drug Name | Target | Indication | Category |
|---|---|---|---|
| Tirzepatide | GIP & GLP-1 receptors | Type 2 diabetes & obesity | Metabolic |
| Semaglutide | GLP-1 receptor | T2DM, obesity, cardiovascular risk | Metabolic |
| Yorvipath | Parathyroid hormone receptor | Hypoparathyroidism | Endocrine |
| Trofinetide | IGF-1 | Rett syndrome (age ≥2) | Neurological |
| Flotufolastat F18 | PSMA | Metastatic prostate cancer | Oncology |
| Melphalan flufenamide | DNA cross-linking | Multiple myeloma | Oncology |
| Zilucoplan | Complement C5 inhibitor | Generalised myasthenia gravis | Immunology |
| Voclosporin | T-cells (calcineurin) | Lupus nephritis | Immunology |
| Motixafortide | CXCR4 antagonist | Stem cell mobilisation (myeloma) | Oncology |
| Rezafungin | β-1,3-glucan synthase | Invasive candidiasis | Antifungal |
| Pegcetacoplan | Complement C3 | Paroxysmal nocturnal haemoglobinuria | Haematology |
| Vosoritide | NPR-B | Achondroplasia | Rare disease |
How Therapeutic Peptides Are Discovered
Starting with Nature's Blueprint
Many approved peptide drugs trace their lineage back to molecules the human body already makes. Native glucagon-like peptide-1 (GLP-1), a 37-amino acid gut hormone that signals satiety and stimulates insulin secretion, has a plasma half-life of less than two minutes — it's cleared almost before it does its job. Rational engineering changed everything. By substituting a single amino acid at position 8 and attaching a fatty acid chain that binds to albumin, researchers created semaglutide — a once-weekly injectable with a half-life of seven days and clinical effects that include significant reductions in cardiovascular events.
"Structural innovations — fatty acid acylation in liraglutide, albumin-binding PEGylation in semaglutide — extend half-lives to enable weekly dosing."— Zheng et al. (2025)
Marine ecosystems have also proven extraordinarily fruitful. Ziconotide, derived from the venom of the cone snail Conus magus, selectively blocks N-type calcium channels to deliver non-opioid pain relief. Plitidepsin, from a sea tunicate, disrupts protein synthesis in cancer cells and has shown efficacy in phase III trials for blood cancers. Nature has spent millions of years selecting for biological potency; drug developers are learning to borrow that wisdom.
Phage Display: A Library of Billions
When you don't know what you're looking for, you need a very large haystack. Phage display threads peptide-encoding DNA into bacteriophages, which then display the corresponding peptides on their surfaces. Libraries exceeding 10 billion distinct sequences can be screened against any target — a receptor, an enzyme, a pathogen surface antigen — and high-affinity binders are progressively enriched through iterative selection cycles.
Early successes included peginesatide, an erythropoietin receptor agonist that mimics the native hormone despite sharing no sequence homology with it. More recently, phage display has been deployed to find peptides that block the PD-1/PD-L1 immune checkpoint, a target central to modern cancer immunotherapy. Innovations such as mirror-image phage display now enable discovery of D-amino acid peptides — structural mirror images that are inherently resistant to the proteolytic enzymes that destroy normal peptides.
The AI Revolution in Peptide Design
AlphaFold3's structural predictions are enabling the design of cyclic peptides against previously "undruggable" targets like the KRAS oncoprotein — implicated in roughly a quarter of all human cancers.
Artificial intelligence has shifted from a supporting role to a central one. Molecular dynamics simulations can now predict how a peptide will fold and bind at atomic resolution, dramatically shortening the design-to-synthesis cycle. Platforms like AlphaFold3 have moved beyond protein structure prediction into antimicrobial peptide design, identifying enzymes capable of degrading bacterial cell walls. AI-driven neoantigen identification pipelines are enabling personalised cancer vaccines tailored to each patient's specific tumour mutations.
The caution, however, is genuine. AI models trained primarily on well-characterised peptide classes perform poorly on unusual architectures — predictions for rare classes like lanthipeptides show root-mean-square deviations above 3.5 Å, compared to below 1.5 Å for standard peptides. The models also tend to optimise for thermodynamic stability over pharmacokinetic parameters, meaning computationally elegant peptides can turn out to be poorly soluble or subtly immunogenic in practice. Hybrid approaches integrating physics-based simulation with experimental validation are now considered the gold standard.
How They Are Made: Chemical vs Biological Synthesis
The production of therapeutic peptides bifurcates into two broad approaches, each with distinct trade-offs.
Solid-phase peptide synthesis (SPPS), pioneered by Robert Merrifield in 1963 — work that earned him the Nobel Prize in Chemistry — remains the workhorse of chemical production. Contemporary versions use microwave-assisted coupling, advanced resin matrices, and automated synthesisers capable of running 192 parallel sequences simultaneously. For longer or more complex molecules, E. coli fed-batch fermentation can yield recombinant insulin at 5 grams per litre, while yeast platforms like Pichia pastoris enable the post-translational modifications required for certain glycopeptide vaccines.
Clinical Frontiers: Where Peptides Are Making Their Mark
Antimicrobial Peptides — A New Front Against Resistant Bacteria
The global rise of multidrug-resistant (MDR) pathogens is one of medicine's defining crises, and conventional antibiotics are losing ground. Antimicrobial peptides (AMPs) offer a fundamentally different mechanism: rather than hitting a single bacterial enzyme (which bacteria can mutate around), most AMPs physically disrupt the bacterial membrane — a target that is much harder to evolve resistance against.
Illustrative importance ranking based on reviewed research literature (Zheng et al., 2025)
Two mammalian AMP families dominate current research: cathelicidins and defensins. In humans, LL-37 is the sole cathelicidin — expressed on respiratory and gastrointestinal epithelial surfaces, it functions as both a direct antimicrobial agent and an immunomodulator. Defensins, structured around three conserved disulfide bonds, are classified into alpha, beta, and theta subfamilies.
Insect-derived AMPs have also reached clinical validation. Alloferon, an 18-amino acid peptide originally isolated from the locust Locusta migratoria, received Russian regulatory approval in 2003 for treating HPV and HSV infections — making it one of the first insect-derived therapeutic peptides to enter clinical use.
Anticancer Peptides and Drug Conjugates
Only 29 of the 460 cancer-targeting agents in current pharmacopoeia databases are peptide or polypeptide-based — roughly 6.3% — but that share is growing rapidly. Anticancer peptides work through four primary mechanisms: immunomodulation of tumour-specific responses, inhibition of blood vessel formation that feeds tumours, interference with transcriptional processes, and direct induction of cancer cell death.
"BT8009 exemplifies this advancement through its Nectin-4-targeting bicyclic peptide structure conjugated to MMAE via cleavable linkers, enabling selective cytotoxicity in Nectin-4-positive tumours."— Zheng et al. (2025), describing a Phase I/II clinical trial result
Peptide-drug conjugates (PDCs) represent the most sophisticated iteration of this concept. They exploit a peptide's targeting precision to deliver a potent cytotoxic payload specifically to tumour cells, sparing healthy tissue. ANG-1005, for instance, uses a blood-brain barrier-penetrating peptide to ferry paclitaxel directly to intracranial tumours — a problem that has stymied conventional chemotherapy for decades. Phase II trial data for breast cancer brain metastases showed reduced systemic toxicity while maintaining efficacy.
Peptide-Based Cancer Vaccines
Perhaps the most transformative application involves training the immune system to recognise and destroy cancer cells. Peptide-based vaccines deliver tumour-associated antigens — particularly neoantigens arising from tumour-specific mutations — to dendritic cells, which then activate cytotoxic T lymphocytes against the tumour.
Cardiovascular and Metabolic Medicine
Cardiovascular disease accounts for 32% of annual global deaths — approximately 17.9 million people per year. Type 2 diabetes prevalence is projected to reach 783 million adults by 2045. GLP-1 receptor agonists have become first-line therapy for patients with both conditions simultaneously, a medical first driven entirely by peptide engineering.
MACE = Major Adverse Cardiovascular Events. Data from cited Phase III trials.
The Remaining Challenges
Honesty demands acknowledging the stubborn barriers that remain. Oral bioavailability for most peptides sits below 1% — the gastrointestinal tract is a hostile environment, combining acidic pH, powerful proteases, and a tight epithelial barrier. Injectable formulations remain the norm, which limits uptake for conditions where daily self-injection is burdensome.
Research into oral peptide delivery is intensifying. Strategies under investigation include mucus-penetrating nanoparticles, pH-responsive enteric coatings that protect peptides through the stomach, and FcRn-targeted carrier systems that hijack the natural pathway the body uses to recycle antibodies. Structural engineering approaches — D-amino acid substitution to resist proteases, backbone cyclisation to lock bioactive conformations, hydrophobic stapling to enforce helical structure — are becoming standard tools in the peptide designer's workshop.
The convergence of AI-driven molecular design, advanced delivery platforms, and regulatory harmonisation under frameworks like ICH Q13 (2025) positions therapeutic peptides as a cornerstone of precision medicine — particularly for oncology, metabolic disorders, and antimicrobial-resistant infections.
Quality control presents its own formidable demands. Minor deviations in amino acid sequence, unintended racemisation at a single residue, or trace impurities from the synthesis process can all compromise pharmacological activity, alter pharmacokinetics, or trigger unwanted immune responses. Regulatory frameworks — the FDA's CMC guidelines, ICH Q6B, and the European Pharmacopoeia standards from EDQM — have become increasingly sophisticated, incorporating high-resolution mass spectrometry, circular dichroism analysis, and multi-attribute monitoring systems to provide comprehensive characterisation.
The Bottom Line
Therapeutic peptides have moved decisively from a niche curiosity to a central pillar of modern pharmacology. The approvals of tirzepatide, semaglutide, and zilucoplan in recent years represent the visible tip of a much larger iceberg — one built from decades of structural biology, synthetic chemistry, and computational innovation.
What makes the next decade especially interesting is the convergence: AI that can design novel peptides in silico, biosynthesis platforms that can produce them sustainably at scale, delivery technologies that are chipping away at the oral bioavailability problem, and personalised medicine paradigms that can match specific peptide sequences to specific patients. The era of one-size-fits-all peptide therapy is already giving way to something far more precise — and far more powerful.
"By synergizing these advancements, next-generation oral peptides hold transformative potential in precision medicine, enabling targeted therapies for oncology, antimicrobial-resistant infections, and metabolic disorders."— Zheng, Wang, Guo & Tzeng (2025), Conclusions
Comments
Post a Comment